Azithromycin. Baseline characteristics were the same in the two groups. The latency period was longer in the Azithromycin group in compare with the Roxithromycin group (14.09 days and 7.87 days respectively, p¼0.003). There was no difference in the rate of chorioamnionitis, the rate of cesarean delivery, Apgar scores and birth weights between the groups CONCLUSION: Among women with preterm PROM between 24 and 34 completed weeks, Azithromycin compared to Roxithromycin is related with longer latency period.
OBJECTIVE:
To determine the pharmacodynamic profile of tranexamic acid (TXA) given at cesarean delivery using rotational thromboelastometry. We expected that as the drug was cleared metabolically, it would be less likely to reverse the ex vivo effect of tissue plasminogen activator (tPA). STUDY DESIGN: We administered 5mg/kg of intravenous tranexamic acid to pregnant women at the time of umbilical cord clamp. Blood samples were collected prior to delivery, after administration within 10 minutes, 30-60 minutes, 1.5-3 hours, 4-6 hours, 7-8 hours and 24 hours. We performed rotational thromboelastometry using EXTEM, APTEM and EXTEM with spiked tPA serially. Inclusion criteria included > 34 weeks gestation, normal renal function and scheduled cesarean delivery. Women were excluded if they had a history of thrombophilia or were on anticoagulation. Our primary outcome was maximum lysis (ML) at 60 minutes in EXTEM samples with tPA over time. We also looked at maximum clot firmness (MCF) prior to and immediately after drug administration. RESULTS: We included 10 women in our study and 9 completed all blood draws. Women were on average 33 AE 4.7 years old, 38 weeks (range 34-39) in gestation and had a body mass index (BMI) of 33.2 AE 7.2 kg/m 2 . ML values for EXTEM with tPA over time are included (Table) . The average ML and standard deviation (SD) are 99.7% (SD 0.5) for pre-delivery and 4.9% (1.8), 14.8% (11.1), 49.9% (35.3), 79.9% (22.7), 86.9% (25.1), 88.3% (31.7) for each corresponding serial blood draw as detailed above. A representative sample of assays over time is included (Figure) . MCF for pre-delivery, 73 AE 3.6 mm, and within 10 minutes of drug administration, 70 AE 6.3 mm, was not different (p¼0.19). CONCLUSION: The effects of tranexamic acid given in vivo appears to reverse the added ex vivo tPA until about 7-8 hours after administration, though there is some variability in drug clearance. There does not appear to be evidence of hypercoagulability by rotational thromboelastometry after TXA administration. There were a total of 275 women (0.5%) who had blood transfusion and 3,717 women (6.6%) with EBL ! 1000cc. Tracking shell level (low/medium/high) designation is significantly associated with all the outcomes examined (Table) . For women with high risk scores, the relative risk ratio compared with low risk women was 4.9 (95% CI 3.2-7.4) for blood transfusion and 5.2 (4.6-5.9) for EBL ! 1000cc. Only 9.5% of women (26/275) who were categorized as low risk for hemorrhage required a blood transfusion. For high versus low risk and the outcome of EBL ! 1000cc, the sensitivity was 85%, specificity was 51%, positive predictive value 10%, negative predictive value 98%.
CONCLUSION: Women who scored high risk for hemorrhage on admission had five times higher risk for blood transfusion and EBL ! 1000cc compared to low risk women. Given the low incidence of the outcomes explored, the hemorrhage risk assessment on admission works moderately well to identify peripartum morbidity.
175 Perinatal outcomes after implementing a hemorrhage risk assessment at admission The George Washington University School of Medicine and Health Sciences, Washington University, DC, 3 Children's National Medical Center, Washington University, DC OBJECTIVE: To evaluate the impact of a novel assessment of hemorrhage risk at admission on subsequent perinatal outcomes. STUDY DESIGN: This retrospective cohort analysis of a multicenter database included women admitted to labor and delivery from January 2015 to June 2018. A novel nursing assessment developed by Association of Women's Health, Obstetric and Neonatal Nurses was used to categorize patients as low, medium or high risk for hemorrhage. This was implemented 6/1/2016 across the centers. Perinatal outcomes related to blood transfusion, estimated blood loss (EBL) ! 1000cc, ICU admission, chorioamnionitis, general anesthesia, oxytocin use and cesarean delivery were evaluated before and after implementation. RESULTS: There were a total of 109,719 women included, with 38,751 women included prior to implementation of the hemorrhage risk assessment and 70,968 women after implementation. Rates of any blood transfusion (0.5 to 0.4%, p¼0.02) and EBL ! 1000cc (6.3 to 6.0%, p¼0.02) were significantly lower after implementation. Incidence of ICU admission, chorioamnionitis and general anesthesia did not change overall in the time period studied. There were higher rates of oxytocin use (83.4 to 85.2%, p<0.0001) and spontaneous vaginal delivery (58.8 to 59.9%, p¼0.01). Details on perinatal outcomes are included (Table) .
CONCLUSION: After implementation of a hemorrhage risk assessment at admission, we found a 20% reduction in rates of blood transfusion and EBL ! 1000cc. Significantly increased oxytocin use was also observed. Further analysis must be done to assess if any other changes could account for these trends.
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